|
1) Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand. 1957; 159: 189-94
|
|
|
|
2) Roeley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in APL. Lancet. 1977; 1: 549-50
|
|
|
|
|
|
3) Kakizuka A, Miller WH, Umesono K, et al. Chromosomal translocation t(15; 17) in human APL fused RAR alpha with a novel putative transcription factor, PML. Cell. 1991; 66: 663-74
|
|
|
|
|
4) Bemard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: result of treatment by daunorubisin. Blood. 1973; 41: 489-96
|
|
|
|
|
|
5) Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988; 72: 567-72
|
|
|
|
|
|
6) Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007; 110: 59-66
|
|
|
|
|
|
7) Sun HD, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide. Chinese J Combinat West Chinese Med. 1992; 12: 170-1
|
|
|
|
|
|
8) Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19: 3852-60
|
|
|
|
|
|
9) Hashimoto Y, Shudo K. Retinoids and their nuclear receptors. Cell Biol Rev. 1991; 25: 209-35
|
|
|
|
|
|
10) Takeuchi M, Yano T, Omoto E, et al. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leuk Lymphoma. 1998; 31(5-6): 441-51
|
|
|
|
|
|
11) Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin(Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004; 104: 1995-9
|
|
|
|
|
|
12) Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101: 5328-35
|
|
|
|
|
|
13) Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006; 107: 3469-73
|
|
|
|
|
|
14) Powell BL, Moser B, Stock W, et al. Consolidation with arsenic trioxide significantly improves EFS and OS among patients with newly diagnosed APL. ASCO. 2008; #7002
|
|
|
|
|
|
15) Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008; 111: 1078-84
|
|
|
|
|
|
16) JALSG APL204プロトコール (委員長 品川克至: 岡山大学医学部 血液・腫瘍内科)
|
|
|
|
|
|
17) de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2005; 23: 120-6
|
|
|
|
|
|
18) Kohno A, Morishita Y, Iida H, et al. Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol. 2008; 87: 210-6
|
|
|
|
|
|
19) JALSG APL205Rプロトコール (委員長 恵美宣彦: 藤田保健衛生大学医学部 血液・化学療法科)
|
|
|
|
|